{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:39:00Z","timestamp":1773297540212,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T00:00:00Z","timestamp":1615161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:p>Emerging data are linking coronavirus disease 2019 (COVID\u201019) with an increased risk of developing new\u2010onset diabetes. The gut has been so far out of the frame of the discussion on the pathophysiology of COVID\u201019\u2010induced diabetes, with the pancreas, liver, and adipose tissue being under the spotlight of medical research. Sodium\u2010glucose co\u2010transporters (SGLT) 1 represent important regulators of glucose absorption, expressed in the small intestine where they mediate almost all sodium\u2010dependent glucose uptake. Similar to what happens in diabetes and other viral infections, SGLT1 upregulation could result in increased intestinal glucose absorption and subsequently promote the development of hyperglycaemia in COVID\u201019. Considering the above, the question whether dual SGLT (1 and 2) inhibition could contribute to improved outcomes in such cases sounds challenging, deserving further evaluation. Future studies need to clarify whether putative benefits of dual SGLT inhibition in COVID\u201019 outweigh potential risks, particularly with respect to drug\u2010induced euglycaemic diabetic ketoacidosis, gastrointestinal side effects, and compromised host response to pathogens.<\/jats:p>","DOI":"10.1111\/bcp.14800","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T00:45:57Z","timestamp":1615250757000},"page":"3643-3646","source":"Crossref","is-referenced-by-count":12,"title":["Intestinal SGLT1 as a therapeutic target in COVID\u201019\u2010related diabetes: A \u201ctwo\u2010edged sword\u201d hypothesis"],"prefix":"10.1111","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1352","authenticated-orcid":false,"given":"Theocharis","family":"Koufakis","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki AHEPA University Hospital  Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-5341","authenticated-orcid":false,"given":"Symeon","family":"Metallidis","sequence":"additional","affiliation":[{"name":"Infectious Diseases Division, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki AHEPA University Hospital  Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8821-406X","authenticated-orcid":false,"given":"Pantelis","family":"Zebekakis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki AHEPA University Hospital  Thessaloniki Greece"},{"name":"Infectious Diseases Division, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki AHEPA University Hospital  Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2376-740X","authenticated-orcid":false,"given":"Kalliopi","family":"Kotsa","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki AHEPA University Hospital  Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,3,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30405-8"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2020.07.002"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108382"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108142"},{"key":"e_1_2_7_6_1","first-page":"1","article-title":"SARS\u2010CoV\u20102 infects and replicates in cells of the human endocrine and exocrine pancreas","author":"M\u00fcller JA","year":"2021","journal-title":"Nat Metab"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110271"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jch.13912"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.11335"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00562.2011"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165585"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479197"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222575"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01511.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.774372"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13630"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.09.019"},{"key":"e_1_2_7_18_1","article-title":"Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure due to COVID\u201019: the design and rationale for the DARE\u201019 study","author":"Kosiborod M","year":"2020","journal-title":"Diabetes Obes Metab"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14800","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14800","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:35:07Z","timestamp":1693355707000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,8]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/bcp.14800"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14800","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,8]]}}}